Category Archives: Bristol-Meyers Squibb

FDA Delays Final OK for Type 2 Drug Empagliflozin

The FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until “previously observed deficiencies” at the plant where it is manufactured are fixed.

The delay does not call into question the safety or utility of …

Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in …